Downregulation of estrogen and progesterone receptors in the abnormal smooth muscle cells in pulmonary lymphangioleiomyomatosis following therapy: An immunohistochemical study

American Journal of Respiratory and Critical Care Medicine

Volumn 161, Issue 3 I, 2000, Pages 1002-1009

  Matsui, Kazuhiro ^b   Takeda, Kazuyo ^b   Yu, Zu Xi ^b   Valencia, Julio ^b   Travis, William D ^b   Moss, Joel ^b   Ferrans, Victor J ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE; ESTROGEN RECEPTOR; PROGESTERONE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; EPITHELIOID CELL; FEMALE; HORMONAL REGULATION; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPHANGIOLEIOMYOMATOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RESPIRATORY TRACT DISEASE; SMOOTH MUSCLE FIBER;

EID: 0034121340     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.161.3.9904009     Document Type: Article

References (31)

1. Corrin, B., A. A. Liebow, and P. J. Friedman. 1975. Pulmonary lymphangiomyomatosis: a review. Am. J. Pathol. 79:348-382.
2. Taylor, J. R., J. Ryu, T. V. Colby, and T. A. Raffin. 1990. Lymphangioleiomyomatosis: clinical course in 32 patients. N. Engl. J. Med. 323: 1254-1260.
3. Kitaichi, M., K. Nishimura, H. Itoh, and T. Izumi. 1995. Pulmonary lymphangioleiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors. Am. J. Respir. Crit. Care Med. 151:527-533.
4. Kalassian, K. G., R. Doyle, P. Kao, S. Ruoss, and T. A. Raffin. 1997. Lymphangioleiomyomatosis: new insights. Am. J. Respir. Crit. Care Med. 155:1183-1186.
5. Carrington, C. B., D. W. Cugell, E. A. Gaensler, A. Marks, R. A. Redding, J. T. Schaaf, and A. Tomasian. 1977. Lymphangioleiomyomatosis: physiologic-pathologic-radiologic correlations. Am. Rev. Respir. Dis. 116:977-995.
6. Brentani, M. M., C. R. Carvalho, P. H. Saldiva, M. M. Pacheco, and C. T. Oshima. 1984. Steroid receptors in pulmonary lymphangiomyomatosis. Cheat 85:96-99.
7. McCarty, K. S. J., J. A. Mossler, R. McLelland, and H. O. Sicker. 1980. Pulmonary lymphangiomyomatosis responsive to progesterone. N. Engl. J. Med. '303:1461-1465.
8. Colley, M. H., E. Geppert, and W. A. Franklin. 1989. Immunohistochemical detection of steroid receptors in a case of pulmonary lymphangioleiomyomatosis. Am. J. Surg. Pathol. 13:803-807.
9. Berger, U., A. Khaghani, A. Pomerance, M. H. Yacoub, and R. C. Coombes. 1990. Pulmonary lymphangioleiomyomatosis and steroid receptors: an immunocytochemical study. Am. J. Clin. Pathol. 93:609-614.
10. Ohori, N. P., S. A. Yousem, E. Sonmez-Alpan, and T. V. Colby. 1991. Estrogen and progesterone receptors in lymphangioleiomyomatosis, epithelioid hemangioendothelioma, and sclerosing hemangioma of the lung. Am. J. Clin. Pathol. 96:529-535.
11. Tazelaar, H. D., D. Kerr, S. A. Yousem, M. J. Saldana, C. Langston, and T. V. Colby. 1993. Diffuse pulmonary lymphangiomatosis. Hum. Pathol. 24:1313-1322.
12. Usuki, J., K. Horiba, S. C. Chu, J. Moss, and V. J. Ferrans. 1998. Immunohistochemical analysis of proteins of the Bcl-2 family in pulmonary lymphangioleiomyomatosis: association of Bcl-2 expression with hormone receptor status. Arch. Pathol. Lab. Med. 122:895-902.
13. Fukuda, Y., M. Kawamoto, A. Yamamoto, M. Ishizaki, F. Basset, and Y. Masugi. 1990. Role of elastic fiber degradation in emphysema-like lesions of pulmonary lymphangiomyomatosis. Hum. Pathol 21:1252-1261.
14. Bonetti, F., M. Pea, G. Martignoni, G. Zamboni, and P. Iuzzolino. 1991. Cellular heterogeneity in lymphangiomyomatosis of the lung. Hum. Pathol. 22:727-728.
15. Bonetti, F., P. L. Chiodera, M. Pea, G. Martignoni, F. Bosi, G. Zamboni, and G. M. Mariuzzi. 1993. Transbronchial biopsy in lymphangiomyomatosis of the lung: HMB45 for diagnosis. Am. J. Surg. Path. 17:1092-1102.
16. Hayashi, T., M. V. Fleming, W. G. Stetler-Stevenson, L. A. Liotta, J. Moss, V. J. Ferrans, and W. D. Travis. 1997. Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM). Hum. Puihol. 28:1071-1078.
17. Fukuda, Y. 1999. Ultrastructural pathology of pulmonary lymphangioleiomyomatosis. In J. Moss, editor. LAM and Other Diseases Characterized by Smooth Muscle Proliferation. Marcel Dekker, New York. 219-239.
18. Travis, W. D., J. Usuki, K. Horiba, and V. J. Ferrans. 1999. Histopathologic studies on lymphangioleiomyomatosis. In J. Moss, editor. LAM and Other Diseases Characterized by Smooth Muscle Proliferation. Marcel Dekker, New York. 171-217.
19. Adema, G. J., A. J. de Boer, A. M. Vogel, W. A. Loenen, and C. G. Figdor. 1994. Molecular characterization of the melanocyte lineage-specific antigen gp100. J. Biol. Chem. 269:20126-20133.
20. Brock, E. T., and J. J. Votto. 1986. Lymphangioleiomyomatosis: treatment with hormonal manipulation. N. Y. State J. Med. 86:533-536.
21. Lockwood, C. J., G. Krikun, V. A. Hausknecht, C. Papp, and F. Schatz. 1998. Matrix metalloproteinase and matrix metalloproteinase inhibitor expression in endometrial stromal cells during progestin-initiated decidualization and menstruation-related progestin withdrawal. Endocrinology 139:4607-4613.
22. Shimonovitz, S., A. Hurwitz, D. Hochner-Celnikier, M. Dushnik, E. Antehy, and S. Yagel. 1998. Expression of gelatinase B by trophoblast cells: down-regulation by progesterone. Am. J. Obstet. Gynecol. 178:457-461.
23. Ioachim, E. E., S. E. Athanassiadou, S. Kamina, K. Carassavoglou, and N. J. Agnantis. 1998. Matrix metalloproteinase expression in human breast cancer: an immunohistochemical study including correlation with cathepsin D, type IV collagen, laminin, fibronectin, EGFR, c-erbB-2 oncoprotein, p53. steroid receptors status and proliferative indices. Anticancer Res. 18:1665-1670.
24. Favoni, R. E., and A. de Cupis. 1998. Steroidal and nonsteroidal oestrogen antagonists in breast cancer: basic and clinical appraisal. Trends Pharmacol. Sci. 19:406-415.
25. Schroen, D. J., and C. E. Brinckerhoff. 1996. Nuclear hormone receptors inhibit matrix metalloproteinase (MMP) gene expression through diverse mechanisms. Gene Expr. 6:197-207.
26. Logan, S. K., M. J. Garabedian, C. E. Campbell, and Z. Werb. 1996. Synergistic transcriplional activation of the tissue inhibitor of metalloproteinases-1 promoter via functional interaction of AP-1 and Ets-1 transcription factors. J. Biol Chem. 271:774-782.
27. Clark, S. D., D. K. Kobayashi, and H. G. Welgus. 1987. Regulation of the expression of tissue inhibitor of metalloproteinases and collagenase by retinoids and glucocorticoids in human fibroblasts. J. Clin. Invest. 80:1280-1288.
28. Sato, T., A. Ito, Y. Mori, K. Yamashita, T. Hayakawa, and H. Nagase. 1991. Hormonal regulation of collagenolysis in uterine cervical fibroblasts: modulation of synthesis of procollagenase, prostromelysin and tissue inhibitor of metalloproteinases (TIMP) by progesterone and oestradiol-17 beta. Biochem. J. 275:645-650.
29. Onate, S. A., S. Y. Tsai, M. J. Tsai, and B. W. O'Malley. 1995. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270:1354-1357.
30. Marbaix, E., J. Donnez, P. J. Courtoy, and Y. Eeckhout. 1992. Progesterone regulates the activity of collagenase and related gelatinases A and B in human endomelrial explants. Proc. Natl. Acad. Sci. U.S.A. 89: 11789-11793.
31. Imada, K., A. Ito, T. Sato, M. Namiki, H. Nagase, and Y. Mori. 1997. Hormonal regulation of matrix metalloproteinase 9/gelatinase B gene expression in rabbit uterine cervical fibroblasts. Biol. Reprod. 56: 575-580.